Keyword: Janssen Biotech

The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.

At last year’s ESC meeting, J&J was touting data that put its clot-busting Xarelto on track for $1 billion-plus in additional sales. Not so this year.

Months ahead of the FDA decision date, the agency approved AbbVie and J&J's Imbruvica, plus Roche's Rituxan, to treat adults with a rare blood cancer.

Healthcare reporters questioned a Johnson & Johnson TV ad for anticoagulant treatment Xarelto, calling out potentially "misleading" visuals.

After reporting phase 2b results for FLU-v, SEEK Group CEO Gregory Stoloff said the program is ready for phase 3.

J&J says Zytiga won't face generics this year, but Sun just won FDA approval for its branded copy, a tweak on the big seller's active ingredient.

Pfizer is counting on some later-stage shots to carry the torch after its blockbuster Prevnar slows down. But it's stocking its early pipeline, too.

AbbVie tried to replace its Imbruvica formula with a single-pill version that cost three times as much for some patients. That didn't go over well.

Inovio's HIV vaccine is in early-stage development, but the company reported immune responses induced by the shot that lasted at least six months.

Tremfya, the next-gen psoriasis biologic from Johnson & Johnson, began airing its first DTC campaign two weeks ago, joining two close rivals on the tube.